Chronic Vulvar Irritation, Itching, and Pain. What Is the Diagnosis?

Total Page:16

File Type:pdf, Size:1020Kb

Chronic Vulvar Irritation, Itching, and Pain. What Is the Diagnosis? SECOND OF 2 PARTS ON OFFICE MANAGEMENT OF BENIGN VULVAR CONDITIONS Chronic vulvar irritation, itching, and pain. What is the diagnosis? Five cases of dermatoses, vaginal abnormalities, and pain syndromes that may masquerade as infection Libby Edwards, MD, and Beth E. Goldbaum, MD hronic irritation, itching, and pain CASE 1 Introital burning and a fear are only rarely due to infection. of breast cancer C These symptoms are more likely to A 56-year-old woman visits your office for be caused by dermatoses, vaginal abnormali- management of recent-onset introital burn- ties, and pain syndromes that may be difficult ing during sexual activity. She reports that to diagnose. Careful evaluation should in- her commercial lubricant causes irritation. clude a wet mount and culture to eliminate Topical and oral antifungal therapies have not infection as a cause so that the correct diag- been beneficial. She has a strong family his- IN THIS nosis can be ascertained and treated. tory of breast cancer. ARTICLE In Part 2 of this two-part series, we focus On examination, she exhibits small, When a woman on five cases of vulvar dermatologic disrup- smooth labia minora and experiences pain is reluctant to use tions: when a cotton swab is pressed against the local estrogen • atrophic vagina vestibule. The vagina is also smooth, with page 32 • irritant and allergic contact dermatitis scant secretions. Microscopically, these • complex vulvar aphthosis secretions are almost acellular, with no • desquamative inflammatory vaginitis increase in white blood cells and no clue A teenager • inverse psoriasis. cells, yeast forms, or lactobacilli. The pH is with vulvar pain greater than 6.5, and most epithelial cells are and sores parabasal (FIGURE 1, page 32). page 34 You prescribe topical estradiol cream Dr. Edwards is Chief of for vaginal use three nights per week, but Dermatology at Carolinas Medical A case of inverse Center, Charlotte, North Carolina. when the patient returns 1 month later, her psoriasis condition is unchanged. She explains that page 36 she never used the cream after reading the package insert, which reports a risk of breast cancer. Dr. Goldbaum is Clinical Instructor of Obstetrics and Gynecology Diagnosis: Atrophic vagina (not atrophic vag- at Harvard Medical School, initis, as there is no increase in white blood Boston, Massachusetts. cells). ›› Read Part 1: Chronic Treatment: Re-estrogenization should relieve vulvar symptoms her symptoms. and dermatologic disruptions (May 2014), The authors report no financial relationships relevant to this article. at obgmanagement.com Several options for local estrogen replace- ment are available. Creams include estradiol CONTINUED ON PAGE 32 30 OBG Management | June 2014 | Vol. 26 No. 6 obgmanagement.com Benign vulvar conditions CONTINUED FROM PAGE 30 FIGURE 1 Atrophic vagina When a woman is reluctant to use local estrogen We counsel women that small doses of vagi- nal estrogen used for limited periods of time are unlikely to influence their breast cancer risk and are the most effective treatment for symptoms of atrophy. Usually, this explana- tion is sufficient to reassure a woman that topical estrogen is safe. Otherwise, use of commercial personal lubricants (silicone- based lubricants are well tolerated) and moisturizers such as Replens and RePhresh can be comforting. The topical anesthetics lidocaine 2% jelly or lidocaine 5% ointment (which sometimes burns) can minimize pain with sexual activity for those requiring more than lubrication. Ospemifene (Osphena) is used by some clinicians in this situation, but this medica- This wet mount of an atrophic vagina shows many parabasal cells with no tion is labeled as a risk for all of the same lactobacilli and no increase in white blood cells. Figure courtesy of Libby Edwards, MD. contraindications as systemic estrogen, and it is much more expensive than topical es- trogen. Ospemifene is an estrogen agonist/ (Estrace) and conjugated equine estrogen antagonist. Although it is the only oral (Premarin), the latter of which is arguably medication indicated for the treatment of The risk of vaginal slightly more irritating. These are prescribed menopause-related dyspareunia, the long- candidiasis is fairly at a starting dose of 1 g in the vagina three term effects on breast cancer risk are un- high during the first nights per week. After several weeks, they known. Also, it has an agonist effect on the 2 or 3 weeks of can be titrated to the lowest frequency that endometrium and, again, the long-term risk re-estrogenization controls symptoms. is unknown. The risk of vaginal candidiasis is fair- Fluconazole use is contraindicated ly high during the first 2 or 3 weeks of re- with ospemifene, as is the use of any estro- estrogenization, so patients should be gen products. warned of this possibility. Also consider prophylactic weekly fluconazole or an CASE 2 Recalcitrant itching, burning, azole suppository two or three times a week and redness for the first few weeks. Estradiol tablets A 25-year-old woman reports anogenital itch- (Vagifem) inserted in the vagina are effec- ing, burning, and redness, which have been tive, less messy, and more expensive, as is present for 3 months. She says she devel- the estradiol ring ( Estring), which is insert- oped a yeast infection after antibiotic therapy ed and changed quarterly. for a dental infection; the yeast infection was It is not unusual for a woman to avoid treated with terconazole. She reports an aller- use of topical estrogen out of fear, or to use gic reaction to the terconazole, with immedi- insufficient amounts only on the vulva, or to ate severe burning, redness, and swelling. use it for only 1 or 2 weeks.1 The clobetasol cream she was given to use Women should be scheduled for a re- twice daily also caused burning, so she dis- turn visit to ensure they have been using the continued it. Her symptoms improved when estrogen, their wet mount has normalized, she tried cool soaks and applied topical ben- and discomfort has cleared. zocaine gel as a local anesthetic. However, 32 OBG Management | June 2014 | Vol. 26 No. 6 obgmanagement.com FIGURE 2 Contact dermatitis exposed to an irritating substance in suf- ficient quantity or frequency. Irritant con- tact dermatitis is characterized mostly by sensations of rawness or burning and generally is caused by urine, feces, perspi- ration, friction, alcohols in topical creams, overwashing, and use of harsh soaps. • Allergic contact dermatitis—This form is characterized by itching, although second- ary pain and burning from scratching and blistering can occur as well. Common aller- gens in the genital area include benzocaine, diphenhydramine (Benadryl), neomycin in triple antibiotic ointment (Neosporin), and latex. Allergic contact dermatitis occurs after 1 or 2 weeks of initial exposure or 1 or 2 days after re-exposure. The diagnosis of an irritant or allergic contact dermatitis can be based on a history of incontinence, application of high-risk sub- stances, or inappropriate washing. Manage- Redness and erosions are typical of an acute contact ment generally involves discontinuation of dermatitis, and eroded papules are especially all panty liners and topical agents except for common in contact dermatitis of benzocaine. Figure courtesy of Libby Edwards, MD. water, with a topical steroid ointment used twice a day and pure petroleum jelly used as often as necessary for comfort. Nighttime se- 2 weeks later, she experienced increasing red- dation to allow a reprieve from rubbing and Diagnosis of an ness, itching, and burning. Although the ben- scratching may be helpful, and narcotic pain irritant or allergic zocaine relieved these symptoms, it required medications may be useful for the first 1 to contact dermatitis almost continual reapplication for comfort. 2 weeks of treatment. can be based A physical examination of the vulva Women who fail to respond to treatment on a history of reveals generalized, poorly demarcated should be referred for patch testing by a incontinence, redness, edema, and superficial erosions dermatologist. application of high- (FIGURE 2). risk substances, Diagnosis: Irritant contact dermatitis (as CASE 3 Teenager with vulvar pain and sores or inappropriate opposed to allergic contact dermatitis) asso- A woman brings her 13-year-old daughter washing ciated with the use of terconazole and clo- to your office for treatment of sudden-onset betasol. This was followed by allergic contact vulvar pain and sores. The child developed a dermatitis in association with benzocaine. sore throat and low-grade fever 3 days ear- Treatment: Withdrawal of benzocaine, with lier, with vulvar pain and vulvar dysuria the reinitiation of cool soaks and a switch to clo- next day. The pediatrician diagnosed a her- betasol ointment rather than cream. Night- pes simplex virus infection and prescribed time sedation allows the patient to sleep oral acyclovir, but the girl’s condition has through the itching and gradually allows her not improved, and the mother believes her skin to heal. daughter’s claims of sexual abstinence. The girl is otherwise healthy, aside from Contact dermatitis is a fairly common cause a history of trivial oral canker sores without of vulvar irritation, with two main types: arthritis, headaches, abdominal pain, eye • Irritant contact dermatitis—The most pain, or vision changes. common form, it occurs in any individual Physical examination of the vulva reveals obgmanagement.com Vol. 26 No. 6 | June 2014 | OBG Management 33 Benign vulvar conditions FIGURE 3 Vulvar aphthae transmitted disease, but the large, well- demarcated, painful, nonindurated deep nature of the ulcer is pathognomonic for an aphthous ulcer. The presence of oral and genital aphthae does not constitute a diagnosis of Behçet disease, an often-devastating systemic in- flammatory condition occurring almost ex- clusively in men in the Middle and Far East. The diagnosis of Behçet disease requires the identification of objective inflammatory dis- ease of the eyes, joints, gastrointestinal tract, or neurologic system.
Recommended publications
  • DESONATE® (Desonide) Gel 0.05% for Topical Use Only • Systemic Absorption May Require Evaluation for HPA Axis Suppression Initial U.S
    HIGHLIGHTS OF PRESCRIBING INFORMATION ----------------------- WARNINGS AND PRECAUTIONS------------------------ These highlights do not include all the information needed to use • Topical corticosteroids can produce reversible hypothalamic pituitary DESONATE Gel safely and effectively. See full prescribing information adrenal (HPA) axis suppression, Cushing's syndrome and unmask latent for DESONATE Gel. diabetes. (5.1) DESONATE® (desonide) Gel 0.05% for topical use only • Systemic absorption may require evaluation for HPA axis suppression Initial U.S. Approval: 1972 (5.1). • Modify use should HPA axis suppression develop (5.1) ---------------------------- INDICATIONS AND USAGE--------------------------- • Potent corticosteroids, use on large areas, prolonged use or occlusive use may increase systemic absorption (5.1) DESONATE is a corticosteroid indicated for the topical treatment of mild to moderate atopic dermatitis in patients 3 months of age and older. (1) • Local adverse reactions may include atrophy, striae, irritation, acneiform eruptions, hypopigmentation, and allergic contact dermatitis and may be ---------------------- DOSAGE AND ADMINISTRATION----------------------- more likely with occlusive use or more potent corticosteroids. (5.2, 5.4, 6) • Apply as a thin layer to the affected areas two times daily and rub in • Children may be more susceptible to systemic toxicity when treated with gently. (2) topical corticosteroids. (5.1, 8.4) • Therapy should be discontinued when control is achieved. (2) • If no improvement is seen within 4 weeks, reassessment of diagnosis ------------------------------ ADVERSE REACTIONS------------------------------- may be necessary. (2) The most common adverse reactions (incidence ≥ 1%) are headache and • Should not be used with occlusive dressings. (2) application site burning. (6) • Treatment beyond 4 consecutive weeks is not recommended. (2) To report SUSPECTED ADVERSE REACTIONS, contact LEO Pharma • For topical use only.
    [Show full text]
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group D07A (Corticosteroids, Plain) Table of Contents Page INTRODUCTION 4 DISCLAIMER 6 GLOSSARY OF TERMS USED IN THIS DOCUMENT 7 ACTIVE SUBSTANCES Methylprednisolone (ATC: D07AA01) 8 Hydrocortisone (ATC: D07AA02) 9 Prednisolone (ATC: D07AA03) 11 Clobetasone (ATC: D07AB01) 13 Hydrocortisone butyrate (ATC: D07AB02) 16 Flumetasone (ATC: D07AB03) 18 Fluocortin (ATC: D07AB04) 21 Fluperolone (ATC: D07AB05) 22 Fluorometholone (ATC: D07AB06) 23 Fluprednidene (ATC: D07AB07) 24 Desonide (ATC: D07AB08) 25 Triamcinolone (ATC: D07AB09) 27 Alclometasone (ATC: D07AB10) 29 Hydrocortisone buteprate (ATC: D07AB11) 31 Dexamethasone (ATC: D07AB19) 32 Clocortolone (ATC: D07AB21) 34 Combinations of Corticosteroids (ATC: D07AB30) 35 Betamethasone (ATC: D07AC01) 36 Fluclorolone (ATC: D07AC02) 39 Desoximetasone (ATC: D07AC03) 40 Fluocinolone Acetonide (ATC: D07AC04) 43 Fluocortolone (ATC: D07AC05) 46 2 Diflucortolone (ATC: D07AC06) 47 Fludroxycortide (ATC: D07AC07) 50 Fluocinonide (ATC: D07AC08) 51 Budesonide (ATC: D07AC09) 54 Diflorasone (ATC: D07AC10) 55 Amcinonide (ATC: D07AC11) 56 Halometasone (ATC: D07AC12) 57 Mometasone (ATC: D07AC13) 58 Methylprednisolone Aceponate (ATC: D07AC14) 62 Beclometasone (ATC: D07AC15) 65 Hydrocortisone Aceponate (ATC: D07AC16) 68 Fluticasone (ATC: D07AC17) 69 Prednicarbate (ATC: D07AC18) 73 Difluprednate (ATC: D07AC19) 76 Ulobetasol (ATC: D07AC21) 77 Clobetasol (ATC: D07AD01) 78 Halcinonide (ATC: D07AD02) 81 LIST OF AUTHORS 82 3 INTRODUCTION The availability of medicines with or without a medical prescription has implications on patient safety, accessibility of medicines to patients and responsible management of healthcare expenditure. The decision on prescription status and related supply conditions is a core competency of national health authorities.
    [Show full text]
  • Steroids Topical
    Steroids, Topical Therapeutic Class Review (TCR) September 18, 2020 No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage or retrieval system without the express written consent of Magellan Rx Management. All requests for permission should be mailed to: Magellan Rx Management Attention: Legal Department 6950 Columbia Gateway Drive Columbia, Maryland 21046 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to [email protected]. September
    [Show full text]
  • Understanding Asthma
    Understanding Asthma The Mount Sinai − National Jewish Health Respiratory Institute was formed by the nation’s leading respiratory hospital National Jewish Health, based in Denver, and top ranked academic medical center the Icahn School of Medicine at Mount Sinai in New York City. Combining the strengths of both organizations into an integrated Respiratory Institute brings together leading expertise in diagnosing and treating all forms of respiratory illness and lung disease, including asthma, chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD) and bronchiectasis. The Respiratory Institute is based in New York City on the campus of Mount Sinai. njhealth.org Understanding Asthma An educational health series from National Jewish Health IN THIS ISSUE What Is Asthma? 2 How Does Asthma Develop? 4 How Is Asthma Diagnosed? 5 What Are the Goals of Treatment? 7 How Is Asthma Managed? 7 What Things Make Asthma Worse and How Can You Control Them? 8 Nocturnal Asthma 18 Occupational Asthma 19 Medication Therapy 20 Monitoring Your Asthma 29 Using an Action Plan 33 Living with Asthma 34 Note: This information is provided to you as an educational service of National Jewish Health. It is not meant as a substitute for your own doctor. © Copyright 1998, revised 2014, 2018 National Jewish Health What Is Asthma? This booklet, prepared by National Jewish Health in Denver, is intended to provide information to people with asthma. Asthma is a chronic respiratory disease — sometimes worrisome and inconvenient — but a manageable condition. With proper understanding, good medical care and monitoring, you can keep asthma well controlled. That’s our treatment goal at National Jewish Health: to teach patients and families how to manage asthma, so that they can lead full and productive lives.
    [Show full text]
  • Medical Review~ Clinical Review
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 21-978 MEDICAL REVIEW~ CLINICAL REVIEW Application Type NDA Submission Number 21-978 Submission Code 000 Letter Date November 18, 2005 Stamp Date November 28, 2005 PDUFA Goal Date September 21,2006 Reviewer Name Denise Cook, M.D. Review Completion Date 8/28/06 Established Name Desonide (Proposed) Trade Name .. Therapeutic Class Topical corticosteroid Applicant Connectics Priority Designatiop S Formulation Foam, 0.05% Dosing Regimen bid Indication F or the treatment of mild to moderate atopic dermatitis . Intended Population Age 3 months and above Clinical Review Denise Cook, M.D. NDA 21-978/ N-OOO _ loam, 0.05%/desonide foam, 0.05% Table of Contents 1 EXECUTIVE SUMMARy................................................................................................................................5 1.1 RECOMMENDATION ON REGULATORY ACTION ...........................................................................................5 1 .2 RECOMMENDATION ON POSTMARKETING ACTIONS. .............. ...... .... .... ........... ........ ..... ... ..... ...... ......... ........5 1.2. I Risk Management Activity................ ......... ..... ............... ..... ................... ........ ........ .... ....... ... ......... ........5 1.2.2 Required Phase 4 Commitments............................................................................................................5 1.2.3 Other Phase 4 Requests..........................................................................................................................5
    [Show full text]
  • Steroid Use in Prednisone Allergy Abby Shuck, Pharmd Candidate
    Steroid Use in Prednisone Allergy Abby Shuck, PharmD candidate 2015 University of Findlay If a patient has an allergy to prednisone and methylprednisolone, what (if any) other corticosteroid can the patient use to avoid an allergic reaction? Corticosteroids very rarely cause allergic reactions in patients that receive them. Since corticosteroids are typically used to treat severe allergic reactions and anaphylaxis, it seems unlikely that these drugs could actually induce an allergic reaction of their own. However, between 0.5-5% of people have reported any sort of reaction to a corticosteroid that they have received.1 Corticosteroids can cause anything from minor skin irritations to full blown anaphylactic shock. Worsening of allergic symptoms during corticosteroid treatment may not always mean that the patient has failed treatment, although it may appear to be so.2,3 There are essentially four classes of corticosteroids: Class A, hydrocortisone-type, Class B, triamcinolone acetonide type, Class C, betamethasone type, and Class D, hydrocortisone-17-butyrate and clobetasone-17-butyrate type. Major* corticosteroids in Class A include cortisone, hydrocortisone, methylprednisolone, prednisolone, and prednisone. Major* corticosteroids in Class B include budesonide, fluocinolone, and triamcinolone. Major* corticosteroids in Class C include beclomethasone and dexamethasone. Finally, major* corticosteroids in Class D include betamethasone, fluticasone, and mometasone.4,5 Class D was later subdivided into Class D1 and D2 depending on the presence or 5,6 absence of a C16 methyl substitution and/or halogenation on C9 of the steroid B-ring. It is often hard to determine what exactly a patient is allergic to if they experience a reaction to a corticosteroid.
    [Show full text]
  • Finding Hazards
    FINDING HAZARDS OSHA 11 Finding Hazards 1 Osha 11 Finding Hazards 2 FINDING HAZARDS Learning Objectives By the end of this lesson, students will be able to: • Define the term “job hazard” • Identify a variety of health and safety hazards found at typical worksites where young people are employed. • Locate various types of hazards in an actual workplace. Time Needed: 45 Minutes Materials Needed • Flipchart Paper • Markers (5 colors per student group) • PowerPoint Slides: #1: Job Hazards #2: Sample Hazard Map #3: Finding Hazards: Key Points • Appendix A handouts (Optional) Preparing To Teach This Lesson Before you present this lesson: 1. Obtain a flipchart and markers or use a chalkboard and chalk. 2. Locate slides #1-3 on your CD and review them. If necessary, copy onto transparencies. 3. For the Hazard Mapping activity, you will need flipchart paper and a set of five colored markers (black, red, green, blue, orange) for each small group. Detailed Instructor’s Notes A. Introduction: What is a job hazard? (15 minutes) 1. Remind the class that a job hazard is anything at work that can hurt you, either physically or mentally. Explain that some job hazards are very obvious, but others are not. In order to be better prepared to be safe on the job, it is necessary to be able to identify different types of hazards. Tell the class that hazards can be divided into four categories. Write the categories across the top of a piece of flipchart paper and show PowerPoint Slide #1, Job Hazards. • Safety hazards can cause immediate accidents and injuries.
    [Show full text]
  • Heavy Menstrual Bleeding
    25/06/2018 Definition • Heavy menstrual bleeding (HMB) is defined as excessive menstrual blood loss which interferes with a woman's physical, social, emotional and/or material quality of life. Heavy Menstrual Bleeding (HMB): Replaced ‘menorrhagia’ Objective definition of HMB >80mL/ cycle or duration of >7 days Causes and Management • It can occur alone or in combination with other symptoms (e.g. intermenstrual bleeding, pelvic pain, pressure symptoms) Dr. William (Wee-Liak) Hoo, MD MRCOG Consultant Gynaecologist Prevalence King’s College Hospital NHS FT • The prevalence of HMB in objective studies (9 to 14%) and subjective studies 20 to 52%) in studies based on subjective assessment. • In the UK, almost 1.5 million women consult their General Practitioners UKCPA Women’s Health Group Masterclass (GPs) each year with menstrual complaints and the annual treatment cost Friday 22nd June 2018 exceeds £65 million. Causes • Uterine: Uterine fibroids (dysmenorrhoea, palpable mass, pressure symptoms) Adenomyosis (dysmenorrhoea, subfertility) Endometrial polyps (intermenstrual bleeding) Pelvic inflammatory disease (PID)/ infection (vaginal discharge, pelvic pain, intermenstrual and postcoital bleeding and pyrexia) Malignancy or atypical hyperplasia (irregular/ postcoital/ intermenstrual bleeding, pelvic pain, weight loss). • Ovarian: Polycystic ovary syndrome (acne, hursuitism) • Systemic diseases: Hypothyroidism (fatigue, constipation, cold intolerance and hair and skin changes) Coagulation disorders (e.g. von Willebrand disease) Liver
    [Show full text]
  • Prevention and Management of Occupational Dermatitis and Latex Allergy in a Healthcare Setting Policy
    Prevention and Management of Occupational Dermatitis and Latex Allergy in a Healthcare Setting Policy V3.0 June 2020 Summary The aim of the policy is to: . protect individuals employed by the Royal Cornwall Hospitals Trust from developing skin conditions through exposure to potential irritants they may encounter whilst at work . describe the occupational health management of those who develop skin conditions . minimise the risks to patients and staff that may arise as a consequence of skin conditions developed by healthcare workers. Posts with specific responsibilities: . ward/departmental managers . individual staff . Occupational Health Service . Health and Safety Team . Infection Prevention and Control Team . Dermatology Department . Procurement Team . Health and Safety Committee. Key points in the document: . the risk of skin problems is increased in those who are exposed to agents through their work that can irritate or sensitise the skin. This can include frequent handwashing and the use of gloves in healthcare workers. Many of the exposures that place those working in a healthcare setting at increased risk are related to infection prevention and control requirements . background information for staff and managers regarding dermatitis and allergy . assessment forms . referral to Occupational Health . reporting of occupational dermatitis. Prevention and Management of Occupational Dermatitis and Latex Allergy in a Healthcare Setting Policy V3.0 Page 2 of 28 Table of Contents Summary ...........................................................................................................................
    [Show full text]
  • Allergic Contact Dermatitis from Formaldehyde Exposure
    DOI: 10.5272/jimab.2012184.255 Journal of IMAB - Annual Proceeding (Scientific Papers) 2012, vol. 18, book 4 ALLERGIC CONTACT DERMATITIS FROM FORMALDEHYDE EXPOSURE Maya Lyapina1, Angelina Kisselova-Yaneva 2, Assya Krasteva2, Mariana Tzekova -Yaneva2, Maria Dencheva-Garova2 1) Department of Hygiene, Medical Ecology and Nutrition, Medical Faculty, 2) Department of Oral and Image Diagnostic, Faculty of Dental Medicine, Medical University, Sofia,Bulgaria ABSTRACT atmospheric air, tobacco smoke, use of cosmetic products Formaldehyde is a ubiquitous chemical agent, a part and detergents, and in less extend – water and food of our outdoor and indoor working and residential consumption (11, 81). It is released into the atmosphere environment. Healthcare workers in difficult occupations are through fumes from automobile exhausts without catalytic among the most affected by formaldehyde exposure. convertors and by manufacturing facilities that burn fossil Formaldehyde is an ingredient of some dental materials. fuels in usual concentration about 1-10 ppb. Uncontrolled Formaldehyde is well-known mucous membrane irritant and forest fires and the open burning of waste also give off a primary skin sensitizing agent associated with both contact formaldehyde. It is believed that the daily exposure from dermatitis (Type IV allergy), and immediate, anaphylactic atmospheric air is up to 0.1 mg (35, 43, 44). reactions (Type I allergy). Inhalation exposure to According to the WHO industrial emissions could formaldehyde was identified as a potential cause of asthma. appear at each step of production, use, transportation, or Quite a few investigations are available concerning health deposition of formaldehyde-containing products. issues for dental students following formaldehyde exposure. Formaldehyde emissions are detected from various Such studies would be beneficial for early diagnosis of industries – energy industry, wood and paper product hypersensitivity, adequate prophylactic, risk assessment and industries, textile production and finishing, chemical management of their work.
    [Show full text]
  • Pre - PA Allowance Age 18 Years of Age Or Older Quantity 60 Grams Every 90 Days ______
    DOXEPIN CREAM 5% (Prudoxin, Zonalon) Pre - PA Allowance Age 18 years of age or older Quantity 60 grams every 90 days _______________________________________________________________ Prior-Approval Requirements Age 18 years of age or older Diagnosis Patient must have the following: Moderate pruritus, due to atopic dermatitis (eczema) or lichen simplex chronicus AND the following: 1. Inadequate response, intolerance or contraindication to ONE medication in EACH of the following categories: a. Topical antihistamine (see Appendix I) b. High potency topical corticosteroid (see Appendix II) 2. Physician agrees to taper patient’s dose to the FDA recommended dose, and after tapered will only use for short-term pruritus relief (up to 8 days) a. Patients using over 60 grams of topical doxepin in 90 days be required to taper to 60 grams topical doxepin within 90 days Prior - Approval Limits Quantity 180 grams for 90 days Duration 3 months ___________________________________________________________________ Prior – Approval Renewal Requirements None (see appendix below) Doxepin 5% cream FEP Clinical Rationale DOXEPIN CREAM 5% (Prudoxin, Zonalon) APPENDIX I Drug Dosage Form Diphenhydramine Cream Phenyltoloxamine Lotion/ Cream Tripelennamine Cream Phendiamine Cream APPENDIX II Relative Potency of Selected Topical Corticosteroid Drug ProductsDosage Form Strength I. Very high potency Augmented betamethasone Ointment, Gel 0.05% dipropionate Clobetasol propionate Cream, Ointment 0.05% Diflorasone diacetate Ointment 0.05% Halobetasol propionate Cream, Ointment 0.05% II. High potency Amcinonide Cream, Lotion, 0.1% Augmented betamethasone Cream,Ointment Lotion 0.05% dipropionate Betamethasone Cream, Ointment 0.05% Betamethasonedipropionate valerate Ointment 0.1% Desoximetasone Cream, Ointment 0.25% Gel 0.05% Diflorasone diacetate Cream, Ointment 0.05% (emollient base) Fluocinonide Cream, Ointment, Gel 0.05% Halcinonide Cream, Ointment 0.1% Triamcinolone acetonide Cream, Ointment 0.5% III.
    [Show full text]
  • The Older Woman with Vulvar Itching and Burning Disclosures Old Adage
    Disclosures The Older Woman with Vulvar Mark Spitzer, MD Itching and Burning Merck: Advisory Board, Speakers Bureau Mark Spitzer, MD QiagenQiagen:: Speakers Bureau Medical Director SABK: Stock ownership Center for Colposcopy Elsevier: Book Editor Lake Success, NY Old Adage Does this story sound familiar? A 62 year old woman complaining of vulvovaginal itching and without a discharge self treatstreats with OTC miconazole.miconazole. If the only tool in your tool Two weeks later the itching has improved slightly but now chest is a hammer, pretty she is burning. She sees her doctor who records in the chart that she is soon everyyggthing begins to complaining of itching/burning and tells her that she has a look like a nail. yeast infection and gives her teraconazole cream. The cream is cooling while she is using it but the burning persists If the only diagnoses you are aware of She calls her doctor but speaks only to the receptionist. She that cause vulvar symptoms are Candida, tells the receptionist that her yeast infection is not better yet. The doctor (who is busy), never gets on the phone but Trichomonas, BV and atrophy those are instructs the receptionist to call in another prescription for teraconazole but also for thrthreeee doses of oral fluconazole the only diagnoses you will make. and to tell the patient that it is a tough infection. A month later the patient is still not feeling well. She is using cold compresses on her vulva to help her sleep at night. She makes an appointment. The doctor tests for BV.
    [Show full text]